Author: cadams
-
Andarix Pharmaceuticals to Present Lung Cancer Clinical Trial Results at international lung cancer meeting
Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present the results of its latest clinical trial in lung cancer patients. The trial focused on the administration of Tozaride, the company’s lead candidate in neuroendocrine lung cancer patients. The data will be presented at…
-
A Billion Dollar Drug Using a Virtual Business Model
Chris Adams, CEO, Andarix, explains how industry can leverage technology to make the drug development process more efficient
-
Andarix Pharmaceuticals Selected to Present at Lung Cancer Summit in Boston, MA
Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, will present at the Precision Lung Cancer Summit in Boston, Massachusetts July 25-26, 2017. Conference location and agenda information are available at the Precision Lung Cancer Conference.
-
Andarix Pharmaceuticals and Wuxi Fortune Pharmaceuticals Sign Drug Deal for China Market
Andarix Pharmaceuticals Inc, a clinical stage company, and Wuxi Fortune Pharmaceuticals announced today the signing of an agreement to develop and commercialize a drug to treat lung and other cancers. As part of the agreement Wuxi Fortune will have certain rights to the China market for Tozaride, a targeted peptide therapy. Wuxi Fortune and Andarix…
-
Andarix Pharmaceuticals Announces Publication of Abstract Describing Lung Cancer Clinical Trial Results at ASCO 2017 Annual Meeting
Andarix Pharmaceuticals, a clinical stage company, announced today the publication of results of a phase1/2 clinical study in lung and neuroendocrine cancer patients. The abstract will be presented at the annual American Society of Clinical Oncology (ASCO) conference in Chicago, IL June 2-6 2017.
-
Andarix Pharmaceuticals’ Targeted Therapy Reduced Tumor Size in Lung Cancer Study
In an open label, single arm study, refractory lung cancer patients to standard of care therapy were identified by image analysis using Rhenium Re 188 P2045, a radiolabeled somatostatin analog. 25 Patients received the imaging dose of 10uCi of Re188 and 265ng of peptide by intravenous injection. Patients were selected based on high SSTR expression levels…
-
Andarix and Tulane University Collaborate to Further Research on Mediators of Cancer Cell Signaling
ANDARIX Pharmaceuticals, a clinical stage company developing targeted peptide therapy for cancers announced today that the Company has entered into an agreement with Tulane University, an institution at the forefront of modern medical innovation, to license the technology and intellectual property concerning Notch Influencing Molecules.
-
Andarix Selected to Present at Prominent Drug Development Conferences
ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for lung and other cancers announced that its Chief Executive Officer, Chris Adams, will present at two upcoming conferences in Boston, MA this fall. Both conferences are invitation only for presenting companies, and showcase leading drug development organizations working to advance groundbreaking…
-
Andarix Selected to Present at Orphan Drug Congress
ANDARIX Pharmaceuticals, a clinical stage company developing a targeted peptide therapy for small cell lung and other cancers announced that its Chief Executive Officer, Chris Adams, will present at the World Orphan Drug Conference in Washington, DC on April 23, 2015. Conference location and agenda information are available at the World Orphan Drug Congress. Andarix’ lead development…
-
Andarix Pharmaceuticals’ Targeted Therapy Demonstrates Efficacy in Pancreatic Cancer
ANDARIX Pharmaceuticals, a clinical stage company, announced today the publication of research findings that demonstrate the ability of its Tozaride targeted peptide therapy to reduce the size of pancreatic cancer tumors. The research paper titled “The Somatostatin Analog Rhenium Re-188-P2045 Inhibits the Growth of AR42J Pancreatic Tumor-Xenografts” was published in the December 1, 2014 issue…